دورية أكاديمية
P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
| العنوان: | P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications. |
|---|---|
| المؤلفون: | da Silveira Júnior LS; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Soares VL; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Jardim da Silva AS; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil.; Faculdade de Ciências da Saúde do Trairi/UFRN, Santa Cruz, Brazil., Gil EA; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Pereira de Araújo MDG; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil.; Laboratório de Citometria de Fluxo, Hemocentro Dalton Cunha, Natal, Brazil., Merces Gonçalves CA; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil.; Laboratório de Citometria de Fluxo, Hemocentro Dalton Cunha, Natal, Brazil., Paiva AS; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Moura de Oliveira TM; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Oliveira GHM; Laboratório de Citometria de Fluxo, Hemocentro Dalton Cunha, Natal, Brazil., Kramer Cavacanti E Silva DG; Faculdade de Ciências da Saúde do Trairi/UFRN, Santa Cruz, Brazil., de Araújo Moura Lemos TM; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Moretti Rebecchi IM; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., de Farias Sales VS; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Luchessi AD; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil., Cavalcanti Júnior GB; Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Rio Grande do Norte (DACT/UFRN), Natal, Brazil.; Laboratório de Citometria de Fluxo, Hemocentro Dalton Cunha, Natal, Brazil. |
| المصدر: | International journal of laboratory hematology [Int J Lab Hematol] 2020 Oct; Vol. 42 (5), pp. 594-603. Date of Electronic Publication: 2020 May 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101300213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-553X (Electronic) Linking ISSN: 17515521 NLM ISO Abbreviation: Int J Lab Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Blackwell Scientific Publications, c2007- |
| مواضيع طبية MeSH: | ATP Binding Cassette Transporter, Subfamily B, Member 1/*genetics , Leukemia, Myeloid, Acute/*diagnosis , Leukemia, Myeloid, Acute/*genetics , Multidrug Resistance-Associated Proteins/*genetics, ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Biomarkers, Tumor ; Child ; Child, Preschool ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Female ; Flow Cytometry ; Humans ; Immunophenotyping ; Infant ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Multidrug Resistance-Associated Proteins/metabolism ; Phenotype ; Prognosis ; Symptom Assessment ; Young Adult |
| مستخلص: | Background: Despite the advances in the cure rate for acute myeloid leukemia (AML), a considerable number of patients die from the disease due to the occurrence of multidrug resistance (MDR). Overexpression of the transporter proteins, such as P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP), confers resistance to the treatment of these leukemias. Methods: To analyze the expression of the Pgp and MRP1 in patients with AML and determine their correlation between expression and demographic, clinical, and laboratorial variables, bone marrow and peripheral blood samples from 346 patients with a diagnosis of AML were assessed for the expression of Pgp and MRP1 by flow cytometry. Results: The expression of Pgp and MRP1 was found in 111 (32.1%) and 133 (38.4%) patients, respectively, with greater prevalence in older patients and lower in children, while also observing a high incidence in patients with refractory, recurrence, and secondary disease in comparison with the cases of de novo AML. Regarding the laboratory findings, we observed an association between the expression of Pgp and MRP1 and CD34, CD7, and also M7, M5a, and M2-AML of French-American-British classification. Conclusions: The results showed that the detection of MDR phenotype by flow cytometry can be a molecular marker for prognosis of patients with AML. (© 2020 John Wiley & Sons Ltd.) |
| References: | Stavrovskaya AA. Cellular mechanism of multidrug resistance of tumor cells. Biochemistry. 2002;65(1):95-106. Gottesman MM. Mechanisms of cancer resistance. Annu Rev Med. 2003;53:615-627. Moraes AC, Maranhão GSR, Santos Silva MC. Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy. J Clin Lab Anal. 2013;100:974-981. Tafuri A, Gregory C, Petrucci MT, et al. MDR-1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974-981. Renes J, de Vries EGE, Jansen PLM, Müler M. The (patho) physiological functions of the MRP family. Drug Res Update. 2003;3:289-302. van den Heuvel-Eibrink MM, Wiemer EAC, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia. 2002;16:833-839. Cavalcanti Júnior GB, Cunha ALA. Estudo de resistência a drogas. In: Duarte AJS, Mirtes Sales M, Moraes VD, eds. Citometria de fluxo aplicações no laboratório clínico e de pesquisa. Chapter 57, S. Paulo, Brazil: Ed Atheneu; 2013: 591-610. Leith CP, Kopecky KJ, Godwin J, et al. Acute Myeloid Leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study. Blood. 1997;89:3323-3329. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glicoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87(5):1997-2004. Figueiredo-Pontes LL, Pintão MCT, Oliveira LCO, et al. Determination of P-glycoprotein, MDR-Related Protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of Acute Myeloid Leukemia. Cytometry part B (Clin Cyt). 2008;74B:163-168. Ying DU, Chen B. Detection approaches for multidrug resistance genes of leukemia. J Clin Lab Anal. 2013;27:62-71. Huet S, Marie JP, Gualde N, et al. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry. 1998;34:248-256. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P glycoprotein associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020. Bennet JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Annals Int Med. 1990;103:620-629. Bain BJ, Swirsky D. Erythrocyte and leucocyte cytochemistry. In: Bain BJ, Bates I, Laffan MA, Lewis SM, eds. Dacie and Lewis Practical Haematology; chapter 15, 11th Ed. London, UK: Elsevier Churchill Livingstone; 2012: 333-352. Bene MC, Castoldi G, Knap W, et al. Proposal for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL). Leukemia. 1995;9:1783-1786. van Dongen JJM, Lhermitte L, Böttcher S, et al. Euro Flow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975. Ikoma MVI, Sandes AF, Thiago LS, et al. First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX. Cytometry part B (Clin Cyt). 2015;88B:194-203. Andrade Alves GV, Fernandes ALC, Freire JM, et al. Flow cytometry immunophenotyping evaluation in acute lymphoblastic leukemia: correlation to factors affecting clinic outcome. J Clin Lab Anal. 2012;26:431-440. Cavalcanti Júnior GB, Scheiner MAM, Simôes Magluta EP, et al. p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinic outcome. Cytometry part B (Clin Cyt). 2010;78B(4):253-259. Cavalcanti Júnior GB, Vasconcelos FC, Faria GP, et al. Co-expression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry Part B (Clin Cyt). 2004;61B:1-8. Walter RB, Raden BW, Hong TC, et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466-1473. Broxterman HJ, Schuurhuis GJ. Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia. J Intern Med Suppl. 1997;740:147-151. Zochbauer S, Schwarzinger I, Strobl H, et al. Relationship between MDR1 gene and surface markers in acute myeloid leukemia. Anticancer Res. 1997;17(1B):749-752. Vasconcelos FC, Cavalcanti Júnior GB, Lani Silva K, et al. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res. 2007;31:445-454. Suárez L, Vidriales MB, Garcia-Laraña J, et al. Multiparametric analysis of apoptotic and multidrug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica. 2001;86:1287-1295. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991;83:708-712. Damiani D, Tiribelli M, Raspadori D, et al. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematol Oncol. 2007;25:38-43. Legrand O, Zompi S, Jean-Yves P, et al. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetic risk groups. Haematologica. 2004;89:34-41. Filipits M, Stranzl T, Pohl G, et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia. 2000;14:68-76. Kappelmayer J, Hevessy Z, Apjok A, Jakab KT. Prediction of therapy response and prognosis in leukemias by flow cytometry MDR assays. JIFCC. 2012;23(4):1-7. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol. 1999;104(2):328-335. Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol. 2002;116(4):834-838. van der Kolk DM, de Vries EGE, van Putten WLJ, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res. 2000;6:3205-3214. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329-337. Saraymen B, Çimen B, Çetin I, et al. Determination of P-glycoprotein expression by flow cytometry in hematological malignancies. Dicle Med J. 2016;43(1):33-38. Miwa H, Kita K, Nishii K, et al. Expression of MDR1 gene in acute leukemia cell: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood. 1993;82:3445-3451. Burger H, Nooter K, Zaman GJR, et al. Expression of multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia. 1994;8(6):990-997. Liu Bei, Li Li-Jun, Gong Xia, Zhang Wei, Zhang Hui, Zhao Li. Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia. Oncol Lett. 2018;15:6671-6677. Rothenberg M, Mickley L, Cole D. Expression of mdr1/Pgp gene in patients with acute lymphoblastic leukemia. Blood. 1989;74:1399-1395. |
| فهرسة مساهمة: | Keywords: P-glycoprotein; acute myeloid leukemia; multidrug resistance; multidrug resistance-associated protein1 |
| المشرفين على المادة: | 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1) 0 (Biomarkers) 0 (Biomarkers, Tumor) 0 (Multidrug Resistance-Associated Proteins) Y49M64GZ4Q (multidrug resistance-associated protein 1) |
| تواريخ الأحداث: | Date Created: 20200527 Date Completed: 20210208 Latest Revision: 20210208 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/ijlh.13241 |
| PMID: | 32452631 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1751-553X |
|---|---|
| DOI: | 10.1111/ijlh.13241 |